Bristol Myers Squibb (CELG-RI) Amortization - Intangibles (2019 - 2026)

Bristol Myers Squibb (CELG-RI) has reported Amortization - Intangibles for 8 consecutive years, with $437.0 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Amortization - Intangibles fell 47.35% year-over-year to $437.0 million; the TTM figure through Jun 2026 stood at $2.5 billion (down 56.05% YoY), while the FY2025 annual figure was $3.3 billion, down 62.61% from the prior year.
• Amortization - Intangibles held at $437.0 million in Q2 2026 per CELG-RI's latest filing, from $437.0 million in the prior quarter.
• Across five years, Amortization - Intangibles topped out at $2.4 billion in Q3 2022 and bottomed at $437.0 million in Q1 2026.
• Historically, Amortization - Intangibles has averaged $1.8 billion across 5 years, with a median of $2.3 billion in 2023.
• Annual changes were most pronounced in 2024 — Amortization - Intangibles rose 7.04% — and 2025, when it slumped 65.65%.
• Bristol Myers Squibb's Amortization - Intangibles stood at $2.3 billion in 2022, then declined by 2.77% to $2.3 billion in 2023, then dropped by 25.68% to $1.7 billion in 2024, then sank by 51.21% to $826.0 million in 2025, then sank by 47.09% to $437.0 million in 2026.
• Business Quant data shows CELG-RI's Amortization - Intangibles at $437.0 million in Q2 2026, $437.0 million in Q1 2026, and $826.0 million in Q4 2025.